Mavenclad helps Merck shrug off Rebif decline in MSAccelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in Share XMavenclad helps Merck shrug off Rebif decline in MShttps://pharmaphorum.com/news/mavenclad-helps-merck-shrug-off-rebif-decline-in-ms/
Merck and Pfizer’s Bavencio approved for renal cell carcinomaMerck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta Share XMerck and Pfizer’s Bavencio approved for renal cell carcinomahttps://pharmaphorum.com/news/merck-and-pfizers-bavencio-approved-for-renal-cell-carcinoma/
Merck and Pfizer stop third Bavencio ovarian cancer trialMerck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced Share XMerck and Pfizer stop third Bavencio ovarian cancer trialhttps://pharmaphorum.com/news/merck-and-pfizer-stop-third-bavencio-ovarian-cancer-trial/
Merck and Pfizer chalk up another fail for BavencioMerck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in Share XMerck and Pfizer chalk up another fail for Bavenciohttps://pharmaphorum.com/news/merck-and-pfizer-chalk-up-another-fail-for-bavencio/
Merck and Pfizer’s immunotherapy combination gains Breakthrough StatusMerck and Pfizer have received a major boost to their immune-oncology alliance with a second FDA Breakthrough Therapy Share XMerck and Pfizer’s immunotherapy combination gains Breakthrough Statushttps://pharmaphorum.com/news/merck-pfizers-immunotherapy-combination-gains-breakthrough-status/
